Skip to content

Protected: Studies

A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis (COMB157G2302)

Calendar Name Ofatumumab
Description This is a Phase III double-blind, double-dummy, parallel group, randomized, active comparator study for relapsing multiple sclerosis patients, using an adaptive design to compare the efficacy and safe
PI Bruce Cohen
People Benjamin Joslin
Business Administrator -
Resources 3T Trio (Neuro)
IRB STU00203803
Start Date 2017-09-18
End Date 2017-12-01
Chart String 640-5210600-60044895
Affiliates No